The Weekly Roundup: April 13-17

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Your Patient Is on a GLP-1: A Dermatologist’s Guide to What Comes Next

Although dermatologists are not expected to routinely prescribe GLP-1 drugs, they are increasingly encountering cutaneous effects, especially hair loss and facial volume loss.

The Cutaneous Connection: Can GLP-1 Therapy Revolutionize Chronic Skin Treatment?

In this episode, Daniel Walker, MD, FAAD, explains how GLP-1 drugs may be effective for psoriasis and HS, linking skin inflammation with weight and heart health.

Systematic Review Identifies Effective CSU Treatment Options

Two oral BTK inhibitors and two injectable biologics demonstrated superior efficacy over placebo in a systematic review of 16 CSU trials.

Delgocitinib Sustains Quality of Life Gains Through 52 Weeks in Chronic Hand Eczema

Work productivity loss fell from 44.3% at baseline to 19.0% at week 52 in the total study population, representing a clinically meaningful reduction in occupational impairment over the full treatment period.

Case Report Identifies Type 1 Hereditary Angioedema in the Context of Omalizumab-Responsive CSU

A rare case shows HAE with chronic spontaneous urticaria; non-itchy facial swelling despite omalizumab signals C4 and C1-INH testing.

Real-World Vitiligo Data Reveal High Discontinuation, Low Persistence Across Therapies

A retrospective claims analysis found that nearly half of patients newly diagnosed with vitiligo by a dermatologist did not initiate therapy, and those who did showed low persistence across treatment categories.

A New Era in Vitiligo Management: From Topicals to Systemic Orals

Oral therapies may provide more widespread and effective repigmentation, especially in extensive nonsegmental vitiligo.

The Sun Bus Delivers Screening, Education, and Research on the Road

Many participants in this mobile screening program have never previously seen a dermatologist.

POLL: When Do You Typically Initiate Biologic Therapy in Patients with CSU?

Take today's poll and explore real-world VHA data showing delayed, low biologic use in chronic spontaneous urticaria, alongside rising ER, inpatient, and outpatient visits after diagnosis.

New Review Details How Sociocultural Context Shapes Vitiligo Patient Outcomes

A new systematic review shows vitiligo’s stigma-driven mental health and quality-of-life burden varies by culture, urging culturally tailored, multidisciplinary care and education.

Large US Cohort Highlights Comorbidity Overlap in Inflammatory Skin Disease

A large All of Us cohort analysis found high rates of obesity and depression in both eczema and psoriasis, reinforcing their systemic nature.

Journal Digest: April 15, 2026

This review of the latest dermatological studies includes insights on the use of microneedling in wound healing, pediatric HS treatment patterns, the role of blood-related phenotypes in hypertrophic scars and keloids, and more.

FDA Accepts sNDA for Delgocitinib Cream to Treat Pediatric Chronic Hand Eczema

FDA will review LEO Pharma's delgocitinib cream for adolescent patients aged 12-17 with CHE, backed by phase 3 gains and addressing a major treatment gap.

Spatial Transcriptomics Reveals How NBUVB Phototherapy Remodels the Immune Landscape in Vitiligo

Spatial transcriptomics reveals how UVB phototherapy calms vitiligo skin, silencing IFN-γ pathways and memory T cells to drive repigmentation.

Real-World Study Quantifies Elevated Autoimmune Risk in US Vitiligo Patients

Elevated rates of herpes simplex, herpes zoster, and opportunistic infections in the vitiligo cohort underscore infection risk considerations.

Study Finds Elevated Acute Stress Risk in Patients With Autoimmune Blistering Diseases

A new case-control study found that patients with pemphigus vulgaris and bullous pemphigoid face more than twice the odds of comorbid acute stress disorder compared with matched controls.

Matching the Molecule to the Patient: Using a 487-GEP Test to Guide AD Treatment Decisions

A new gene expression profiling test may transform how clinicians select systemic treatments for moderate to severe atopic dermatitis.

Cosmo Pharmaceuticals Reports Positive 12-Month Safety Data for Clascoterone 5% in Male AGA

Phase 3 data show clascoterone solution sustains hair regrowth for 12 months with vehicle-like safety, paving the way for a novel male androgenetic alopecia option.

CHECK-US Data Reveal Demographic Splits in How Patients Perceive CHE Causes

The CHECK-US study found that patients commonly perceive their CHE as driven by overlapping environmental, biological, psychological, and lifestyle factors.

A Legacy of Leadership: A Conversation with Henry W. Lim, MD, FAAD, AAD Gold Medal Recipient

Henry W. Lim, MD, FAAD's legacy highlights the impact of mentorship, research, and global advocacy in advancing inclusive dermatologic care and improving skin health worldwide.

Rosacea Uncovered: Current Practices and Therapies on the Horizon

Dysregulation of the innate immune system, inflammatory cytokines, and abnormal blood vessel growth plays a key role in persistent redness and flushing.

Post Hoc Analysis Shows Dupilumab Improves PAS Scores in Patients with Prurigo Nodularis

Pooled phase 3 data show dupilumab rapidly reduces prurigo nodularis activity, cuts excoriations, and boosts healing by week 24 versus placebo.

5-Star Dermatology Is Built, Not Assumed

Kathleen Moe, MD, offers guidance on creating 5-star dermatology patient experience systems for faster access, consistent scripts, and guided checkout that reduce callbacks and build trust.